Medimmune Limited

Daniel E Berkowitz

Andrew Grier Buchanan

Matthieu Chodorge

Peter Cariuk

Clare Balendran

Deepesh Pandey

Fumin Chang

Johanna Husmark

Lewis H Romer

This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.

Antibodies specific for LOX1 and use in treatment of cardiovascular disorders

Growing community of inventors

Baltimore, MD, United States of America

Daniel E Berkowitz